ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO011

Bilirubin Removal by Plasmafiltration-Adsorption: Ex Vivo Adsorption Kinetic Model

Session Information

  • Bioengineering
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 300 Bioengineering


  • Marcello, Matteo, International Renal Research Institute of Vicenza, Vicenza, Italy
  • Lorenzin, Anna, Ospedale San Bortolo di Vicenza, Vicenza, Italy
  • de Cal, Massimo, Ospedale San Bortolo di Vicenza, Vicenza, Italy
  • Ronco, Claudio, International Renal Research Institute of Vicenza, Vicenza, Italy
  • Zanella, Monica, Ospedale San Bortolo di Vicenza, Vicenza, Italy

The removal of bilirubin form blood in patients with severe liver dysfunction is an important blood purification goal. Accordingly, we conducted an ex-vivo study to assess the ability of a novel bilirubin adsorptive cartridge to remove bilirubin from plasma.


We studied the BS330 Plasma Bilirubin Adsorption Column cartridge (Jafron Biomedical, Zhuhai City, China). Our experiment was conducted using a minimodule downscaled 1:3 containing approximately 131 g of BS330 sorbent bead. Using a dedicated machine for extracorporeal treatment simulation named GALILEO, we set up an ex-vivo circulation experiment in which a solution of hyperbilirubinemic plasma was pumped in the circuit and through the cartridge (Figure). Using synthetic bilirubin powder, we obtained a plasma solution with a bilirubin concentration of 92.8 mg/dL. The adsorption trend was evaluated as the bilirubin concentration gap (ΔC) between inlet (Cpin) and outlet (Cpout) lines. Removal ratio (RR) at a given time point was calculated as mass adsorbed at a given time point.


The change in concentration across the cartridge at 30 minutes was 16.5%. The capacity of the cartridge to adsorb bilirubin and cartridge saturation was reached at 750 minutes,759 mg of bilirubin has been retained with a Removal Ratio of 78.1 %. Therefore, the adsorption capacity of the resin was estimated at 5.76 mg of bilirubin per gram of sorbent. The dynamic adsorption curve (Figure) indicates a fast and efficient removal of bilirubin by BS330 in the beginning of perfusion with a Removal Ratio of 42.6% at 120 minutes.


Our findings provide the first assessment of bilirubin adsorption in an ex-vivo model of plasma perfusion and can be used to design interventional studies in humans with appropriately sized cartridges applied for an optimal time period.

Bilirubin adsorption kinetics. Blue line represents the fall of bilirubin concentration during time. Vertical bars represent total mass adsorbed at each time point.